Sanofi (SNY) said Wednesday the US Food and Drug Administration has approved the expanded use of Tzield to delay progression to stage 3 type 1 diabetes in children as young as one year of age with stage 2 disease from at least eight years.
Separately, Sanofi said the FDA has extended by up to three months its review of the company's application for a subcutaneous version of Sarclisa for multiple myeloma, setting a new decision date of July 23.
Sarclisa would be the first anticancer treatment administered via an on-body injector, if approved, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments